loadpatents
Patent applications and USPTO patent grants for Albrecht; Jana.The latest application filed is for "anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123".
Patent | Date |
---|---|
Anti-cd3 Antibodies, Anti-cd123 Antibodies And Bispecific Antibodies Specifically Binding To Cd3 And/or Cd123 App 20210292423 - Albrecht; Jana ;   et al. | 2021-09-23 |
Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 Grant 10,906,978 - Albrecht , et al. February 2, 2 | 2021-02-02 |
Bispecific Antibody-like Binding Proteins Specifically Binding To Cd3 And Cd123 App 20190241657 - ALBRECHT; Jana ;   et al. | 2019-08-08 |
Anti-cd3 Antibodies, Anti-cd123 Antibodies And Bispecific Antibodies Specifically Binding To Cd3 And/or Cd123 App 20180222987 - Albrecht; Jana ;   et al. | 2018-08-09 |
Anti-cd3 Antibodies, Anti-cd123 Antibodies And Bispecific Antibodies Specifically Binding To Cd3 And/or Cd123 App 20180057597 - ALBRECHT; Jana ;   et al. | 2018-03-01 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.